董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Yang Lu | 男 | Chairman of the Board,Chief Executive Officer and Director | 47 | 未披露 | 1699.00 | 2026-04-10 |
| Ping Ji | 女 | Director | 62 | 未披露 | 未持股 | 2026-04-10 |
| Lars Erik Birgerson | 男 | Director | 74 | 未披露 | 未持股 | 2026-04-10 |
| Shaorong Liu | 男 | Independent Director | 48 | 未披露 | 未持股 | 2026-04-10 |
| Ming Lun Alan Tse | 男 | Independent Director | 46 | 未披露 | 未持股 | 2026-04-10 |
| Roger Sawhney | 男 | Independent Director | 57 | 未披露 | 未持股 | 2026-04-10 |
| Baozhong Wei | 男 | Independent Director | 48 | 未披露 | 未持股 | 2026-04-10 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Yang Lu | 男 | Chairman of the Board,Chief Executive Officer and Director | 47 | 未披露 | 1699.00 | 2026-04-10 |
| Xiaofeng Ye | 男 | Chief Financial Officer | 48 | 未披露 | 未持股 | 2026-04-10 |
| Archie Tse | 男 | President and Head of Research & Development | 59 | 未披露 | 未持股 | 2026-04-10 |
董事简历
中英对照 | 中文 | 英文- Yang Lu
-
暂无中文简介
Yang Lu serves as Adlai Nortye Ltd.'s chief executive officer and the chairman of Adlai Nortye Ltd.'s board of directors. Mr. Lu has over 20 years of experience in the pharmaceutical industry. Prior to founding Adlai Nortye Ltd.'s company, Mr. Lu worked at Hybio Pharmaceutical Co., Ltd from April 2003 to March 2004. Mr. Lu obtained his bachelor's degree in biotechnology from Xiamen University in July 2002, and his EMBA Executive Master of Business Administration from China Europe International Business School in September 2012. -
暂无中文简介
- Yang Lu serves as Adlai Nortye Ltd.'s chief executive officer and the chairman of Adlai Nortye Ltd.'s board of directors. Mr. Lu has over 20 years of experience in the pharmaceutical industry. Prior to founding Adlai Nortye Ltd.'s company, Mr. Lu worked at Hybio Pharmaceutical Co., Ltd from April 2003 to March 2004. Mr. Lu obtained his bachelor's degree in biotechnology from Xiamen University in July 2002, and his EMBA Executive Master of Business Administration from China Europe International Business School in September 2012.
- Ping Ji
-
Ping Ji自2023年9月起担任Adlai Nortye Ltd.的董事。她在生物制药药物开发方面拥有超过25年的经验。自2017年7月起，Dr. Ji在美国Kyowa Kirin Co.，Ltd.担任全球安全负责人。在此之前，2011年8月至2017年7月，她在美国拜耳医药保健公司担任全球安全负责人。Ji博士还曾于2006年12月至2011年7月在美国Taiho担任医疗安全主管，于2004年6月至2006年12月在美国Bristol Myers Squibb公司担任医学审评员，于2002年9月至2004年6月在美国赛诺菲 S.A.担任临床科学家。在此之前的2000年9月至2002年9月，她在辉瑞公司担任临床科学家。Ji博士于1993年5月从罗格斯大学研究生院新布朗斯威克、新泽西州立大学和美国罗伯特伍德约翰逊医学院UMDNJ生物医学科学研究生院联合提供的细胞生物学项目获得医学硕士学位。1986年8月获得中国首都医学研究院医学博士学位。
Ping Ji has served as Adlai Nortye Ltd.'s director since September 2023. She has over 25 years of experience in biopharmaceutical drug development. Since July 2017, Dr. Ji served as the global safety leader at Kyowa Kirin Co., Ltd. in the United States. Before that, from August 2011 to July 2017, she served as the global safety leader at Bayer HealthCare Pharmaceuticals Inc. in the United States. Dr. Ji has also served as the medical safety lead at Taiho in the United States from December 2006 to July 2011, as a medical reviewer at Bristol Myers Squibb Company in the United States from June 2004 to December 2006, and as a clinical scientist at Sanofi S.A. in the United States from September 2002 to June 2004. Prior to that, from September 2000 to September 2002, she worked as a clinical scientist at Pfizer Corporation. Dr. Ji obtained her Master of Medicine from the cell biology program offered jointly by Graduated School New Brunswick at Rutgers, the state University of New Jersey and the UMDNJ Graduate School of Biomedical Sciences at Robert Wood Johnson Medical School in the United States in May 1993. She obtained her doctor of medicine from Capital Institute of Medicine in the PRC in August 1986. - Ping Ji自2023年9月起担任Adlai Nortye Ltd.的董事。她在生物制药药物开发方面拥有超过25年的经验。自2017年7月起，Dr. Ji在美国Kyowa Kirin Co.，Ltd.担任全球安全负责人。在此之前，2011年8月至2017年7月，她在美国拜耳医药保健公司担任全球安全负责人。Ji博士还曾于2006年12月至2011年7月在美国Taiho担任医疗安全主管，于2004年6月至2006年12月在美国Bristol Myers Squibb公司担任医学审评员，于2002年9月至2004年6月在美国赛诺菲 S.A.担任临床科学家。在此之前的2000年9月至2002年9月，她在辉瑞公司担任临床科学家。Ji博士于1993年5月从罗格斯大学研究生院新布朗斯威克、新泽西州立大学和美国罗伯特伍德约翰逊医学院UMDNJ生物医学科学研究生院联合提供的细胞生物学项目获得医学硕士学位。1986年8月获得中国首都医学研究院医学博士学位。
- Ping Ji has served as Adlai Nortye Ltd.'s director since September 2023. She has over 25 years of experience in biopharmaceutical drug development. Since July 2017, Dr. Ji served as the global safety leader at Kyowa Kirin Co., Ltd. in the United States. Before that, from August 2011 to July 2017, she served as the global safety leader at Bayer HealthCare Pharmaceuticals Inc. in the United States. Dr. Ji has also served as the medical safety lead at Taiho in the United States from December 2006 to July 2011, as a medical reviewer at Bristol Myers Squibb Company in the United States from June 2004 to December 2006, and as a clinical scientist at Sanofi S.A. in the United States from September 2002 to June 2004. Prior to that, from September 2000 to September 2002, she worked as a clinical scientist at Pfizer Corporation. Dr. Ji obtained her Master of Medicine from the cell biology program offered jointly by Graduated School New Brunswick at Rutgers, the state University of New Jersey and the UMDNJ Graduate School of Biomedical Sciences at Robert Wood Johnson Medical School in the United States in May 1993. She obtained her doctor of medicine from Capital Institute of Medicine in the PRC in August 1986.
- Lars Erik Birgerson
-
Lars Erik Birgerson自2023年9月起担任Adlai Nortye Ltd.的董事。2018年7月至2024年7月担任Adlai Nortye USA INC总裁兼首席执行官，2021年7月至2024年7月担任Adlai Nortye Ltd.首席医疗官。Birgerson博士在制药行业拥有超过32年的经验。在加入Adlai Nortye Ltd.之前，Birgerson博士曾在瑞士巴塞尔的罗氏制药公司担任副总裁兼全球和美国医疗事务主管；在美国加利福尼亚州的基因泰克公司担任医疗事务副总裁；在美国新泽西州的BMS担任医疗事务高级副总裁。从2016年1月至今，Birgerson博士担任美国新泽西州Birgerson集团的总裁和高级顾问。自2016年2月起，Birgerson博士还担任迪卡斯公司的全球医疗顾问。Birgerson博士分别于1977年6月和1990年6月在瑞典乌普萨拉的乌普萨拉大学获得医学博士和哲学博士学位。Birgerson博士自1984年12月14日以来一直是瑞典国家卫生和福利委员会认证的妇产科专家。此外，他于1980年2月19日被瑞典国家健康和福利委员会认证为执业医师。
Lars Erik Birgerson has served as Adlai Nortye Ltd.'s director since September 2023. He served as the president and chief executive officer of Adlai Nortye USA INC from July 2018 to July 2024 and served as Adlai Nortye Ltd.'s chief medical officer from July 2021 to July 2024. Dr. Birgerson has more than 32 years of experience in the pharmaceutical industry. Prior to joining Adlai Nortye Ltd., Dr. Birgerson served as the vice president and head of global and US medical affairs at Roche Pharmaceuticals in Basel, Switzerland; the vice president of medical affairs at Genentech in California, the United States; and the senior vice president of medical affairs at BMS in New Jersey, the United States. From January 2016 to date, Dr. Birgerson has served as the president and senior advisor of The Birgerson Group in New Jersey, the United States. Since February 2016, Dr. Birgerson has also served as the global medical consultant of Delcath Systems Inc. Dr. Birgerson received his Doctor of Medicine and doctorate of philosophy from Uppsala University at Uppsala, Sweden in June 1977 and June 1990 respectively. Dr. Birgerson has been a specialist of obstetrics and gynecology certified by the National Swedish Board of Health and Welfare since December 14, 1984. Further, he was certified as a licensed physician by the National Swedish Board of Health and Welfare in Sweden on February 19, 1980. - Lars Erik Birgerson自2023年9月起担任Adlai Nortye Ltd.的董事。2018年7月至2024年7月担任Adlai Nortye USA INC总裁兼首席执行官，2021年7月至2024年7月担任Adlai Nortye Ltd.首席医疗官。Birgerson博士在制药行业拥有超过32年的经验。在加入Adlai Nortye Ltd.之前，Birgerson博士曾在瑞士巴塞尔的罗氏制药公司担任副总裁兼全球和美国医疗事务主管；在美国加利福尼亚州的基因泰克公司担任医疗事务副总裁；在美国新泽西州的BMS担任医疗事务高级副总裁。从2016年1月至今，Birgerson博士担任美国新泽西州Birgerson集团的总裁和高级顾问。自2016年2月起，Birgerson博士还担任迪卡斯公司的全球医疗顾问。Birgerson博士分别于1977年6月和1990年6月在瑞典乌普萨拉的乌普萨拉大学获得医学博士和哲学博士学位。Birgerson博士自1984年12月14日以来一直是瑞典国家卫生和福利委员会认证的妇产科专家。此外，他于1980年2月19日被瑞典国家健康和福利委员会认证为执业医师。
- Lars Erik Birgerson has served as Adlai Nortye Ltd.'s director since September 2023. He served as the president and chief executive officer of Adlai Nortye USA INC from July 2018 to July 2024 and served as Adlai Nortye Ltd.'s chief medical officer from July 2021 to July 2024. Dr. Birgerson has more than 32 years of experience in the pharmaceutical industry. Prior to joining Adlai Nortye Ltd., Dr. Birgerson served as the vice president and head of global and US medical affairs at Roche Pharmaceuticals in Basel, Switzerland; the vice president of medical affairs at Genentech in California, the United States; and the senior vice president of medical affairs at BMS in New Jersey, the United States. From January 2016 to date, Dr. Birgerson has served as the president and senior advisor of The Birgerson Group in New Jersey, the United States. Since February 2016, Dr. Birgerson has also served as the global medical consultant of Delcath Systems Inc. Dr. Birgerson received his Doctor of Medicine and doctorate of philosophy from Uppsala University at Uppsala, Sweden in June 1977 and June 1990 respectively. Dr. Birgerson has been a specialist of obstetrics and gynecology certified by the National Swedish Board of Health and Welfare since December 14, 1984. Further, he was certified as a licensed physician by the National Swedish Board of Health and Welfare in Sweden on February 19, 1980.
- Shaorong Liu
-
刘绍荣自2023年9月起担任Adlai Nortye Ltd.独立董事。刘先生在企业管理和咨询方面拥有约15年的经验。刘先生自2008年4月起担任上海智易企业管理咨询有限公司的管理合伙人和高级顾问。此外，刘先生还自2018年4月起担任江苏同创草业股份有限公司（上海证券交易所股票代码：605099）的独立非执行董事。刘先生于2012年9月获得中欧国际工商学院工商管理硕士学位。
Shaorong Liu has served as Adlai Nortye Ltd.'s independent director since September 2023. Mr. Liu has approximately 15 years of experience in business management and consulting. Mr. Liu has been serving as the managing partner and senior consultant of Shanghai Zhiyi Enterprise Management Consulting Co., Ltd. since April 2008. Further, Mr. Liu has also been an independent non executive director of Jiangsu CoCreation Grass Co., Ltd. (Shanghai Stock Exchange stock code: 605099) since April 2018. Mr. Liu obtained his master's degree in business administration from the China Europe International Business School in September 2012. - 刘绍荣自2023年9月起担任Adlai Nortye Ltd.独立董事。刘先生在企业管理和咨询方面拥有约15年的经验。刘先生自2008年4月起担任上海智易企业管理咨询有限公司的管理合伙人和高级顾问。此外，刘先生还自2018年4月起担任江苏同创草业股份有限公司（上海证券交易所股票代码：605099）的独立非执行董事。刘先生于2012年9月获得中欧国际工商学院工商管理硕士学位。
- Shaorong Liu has served as Adlai Nortye Ltd.'s independent director since September 2023. Mr. Liu has approximately 15 years of experience in business management and consulting. Mr. Liu has been serving as the managing partner and senior consultant of Shanghai Zhiyi Enterprise Management Consulting Co., Ltd. since April 2008. Further, Mr. Liu has also been an independent non executive director of Jiangsu CoCreation Grass Co., Ltd. (Shanghai Stock Exchange stock code: 605099) since April 2018. Mr. Liu obtained his master's degree in business administration from the China Europe International Business School in September 2012.
- Ming Lun Alan Tse
-
明伦Alan Tse自2023年9月起担任Adlai Nortye Ltd.独立董事。谢先生在财务管理和会计方面拥有20多年的经验。谢先生目前担任天鸽互动控股有限公司（港交所：1980）的独立非执行董事。此前，谢先生曾于2002年9月至2005年5月在毕马威会计师事务所担任会计师，于2005年5月至2007年5月在Techtronic Industries Co.，Ltd担任高级分析师。谢先生还曾于2007年9月至2009年8月在Next Horizon Company Limited担任企业规划和发展高级经理、企业规划和发展高级经理，并于2009年9月至2011年10月在Richemont Asia Pacific Limited担任财务和行政部项目和业务发展经理。Tse先生于2011年11月至2023年12月担任捷成资本总经理。谢先生于2002年12月获得香港大学会计及金融工商管理学士学位。自2005年12月起，他一直是特许公认会计师公会（ACCA）的资深会员。
Ming Lun Alan Tse has served as Adlai Nortye Ltd.'s independent director since September 2023. Mr. Tse has more than 20 years of experience in financial management and accounting. Mr. Tse currently serves as an independent non executive director of Tian Ge Interactive Holdings Ltd. (HKEx: 1980). Previously, Mr. Tse served as an accountant at KPMG from September 2002 to May 2005, a senior analyst at Techtronic Industries Co., Ltd from May 2005 to May 2007. Mr. Tse also served as a senior manager of corporate planning and development, a senior manager of corporate planning and development at Next Horizon Company Limited from September 2007 to August 2009, and a project and business development manager of finance and administration department at Richemont Asia Pacific Limited from September 2009 to October 2011. Mr. Tse served as a general manager of Jebsen Capital from November 2011 to December 2023. Mr. Tse obtained his Bachelor of Business Administration in accounting and finance from the University of Hong Kong in December 2002. He has been a fellow member of the Association of Chartered Certified Accountants (ACCA) since December 2005. - 明伦Alan Tse自2023年9月起担任Adlai Nortye Ltd.独立董事。谢先生在财务管理和会计方面拥有20多年的经验。谢先生目前担任天鸽互动控股有限公司（港交所：1980）的独立非执行董事。此前，谢先生曾于2002年9月至2005年5月在毕马威会计师事务所担任会计师，于2005年5月至2007年5月在Techtronic Industries Co.，Ltd担任高级分析师。谢先生还曾于2007年9月至2009年8月在Next Horizon Company Limited担任企业规划和发展高级经理、企业规划和发展高级经理，并于2009年9月至2011年10月在Richemont Asia Pacific Limited担任财务和行政部项目和业务发展经理。Tse先生于2011年11月至2023年12月担任捷成资本总经理。谢先生于2002年12月获得香港大学会计及金融工商管理学士学位。自2005年12月起，他一直是特许公认会计师公会（ACCA）的资深会员。
- Ming Lun Alan Tse has served as Adlai Nortye Ltd.'s independent director since September 2023. Mr. Tse has more than 20 years of experience in financial management and accounting. Mr. Tse currently serves as an independent non executive director of Tian Ge Interactive Holdings Ltd. (HKEx: 1980). Previously, Mr. Tse served as an accountant at KPMG from September 2002 to May 2005, a senior analyst at Techtronic Industries Co., Ltd from May 2005 to May 2007. Mr. Tse also served as a senior manager of corporate planning and development, a senior manager of corporate planning and development at Next Horizon Company Limited from September 2007 to August 2009, and a project and business development manager of finance and administration department at Richemont Asia Pacific Limited from September 2009 to October 2011. Mr. Tse served as a general manager of Jebsen Capital from November 2011 to December 2023. Mr. Tse obtained his Bachelor of Business Administration in accounting and finance from the University of Hong Kong in December 2002. He has been a fellow member of the Association of Chartered Certified Accountants (ACCA) since December 2005.
- Roger Sawhney
-
Roger Sawhney于2024年8月至2025年7月期间担任Adlai Nortye Ltd.的董事，随后从董事重新指定为独立董事。他在生命科学行业拥有近三十年的财务和战略专长。Sawhney博士目前担任LB Pharmaceuticals的首席财务官，LB Pharmaceuticals是一家专注于神经心理的公司，总部位于纽约市。2022年9月至2023年12月，Sawhney博士担任Garuda Therapeutics，Inc.的首席财务官。2020年3月至2022年5月，Sawhney博士担任Omega Therapeutics, Inc.（一家基于mRNA的精准基因调节疗法的先驱）的首席财务官，并于2022年5月至2022年9月担任Omega的首席商务官。2018年9月至2020年8月，Sawhney博士在全球投资公司KKR & Co. Inc.任职，担任其美洲医疗保健投资平台的董事，他的工作重点是医疗保健领域的私人和成长型股权投资。2009年7月至2012年8月，Sawhney博士担任诺华公司高级副总裁兼全球企业战略主管，并于2017年2月至2018年2月担任Outcome Health公司战略和业务发展高级副总裁。Sawhney博士还曾于2012年8月至2017年2月担任贝恩公司合伙人，并于1996年至2009年担任波士顿咨询公司合伙人，负责管理生命科学、医疗技术和数字健康领域的众多客户业务。Sawhney博士拥有哈佛医学院的医学博士学位和斯坦福大学的经济学学士学位。
Roger Sawhney served as Adlai Nortye Ltd.'s director from August 2024 to July 2025 and subsequently re designation from a director to an independent. He has nearly thirty years of financial and strategic expertise across the life sciences industry. Dr. Sawhney currently serves as the Chief Financial Officer of LB Pharmaceuticals, a neuro psych focused Company, based in New York City. From September 2022 to December 2023, Dr. Sawhney served as the Chief Financial Officer of Garuda Therapeutics, Inc. From March 2020 to May 2022, Dr. Sawhney served as the Chief Financial Officer of Omega Therapeutics, Inc., a pioneer in mRNA based therapeutics for precision gene modulation, and he served as the Chief Business Officer of Omega from May 2022 to September 2022. From September 2018 to August 2020, Dr. Sawhney served at KKR & Co. Inc., a global investment firm, as Director of its healthcare investment platform in the Americas where his work focused on investments across private and growth equity in the healthcare sector. From July 2009 to August 2012, Dr. Sawhney served as Senior Vice President and Head of Global Corporate Strategy for Novartis AG, as well as Senior Vice President of Corporate Strategy and Business Development for Outcome Health from February 2017 to February 2018. Dr. Sawhney also served as Partner with Bain & Company from August 2012 to February 2017 and the Boston Consulting Group from 1996 to 2009, where he managed numerous client engagements across the life sciences, med tech and digital health sectors. Dr. Sawhney holds an M.D. from Harvard Medical School and a B.A. in Economics from Stanford University. - Roger Sawhney于2024年8月至2025年7月期间担任Adlai Nortye Ltd.的董事，随后从董事重新指定为独立董事。他在生命科学行业拥有近三十年的财务和战略专长。Sawhney博士目前担任LB Pharmaceuticals的首席财务官，LB Pharmaceuticals是一家专注于神经心理的公司，总部位于纽约市。2022年9月至2023年12月，Sawhney博士担任Garuda Therapeutics，Inc.的首席财务官。2020年3月至2022年5月，Sawhney博士担任Omega Therapeutics, Inc.（一家基于mRNA的精准基因调节疗法的先驱）的首席财务官，并于2022年5月至2022年9月担任Omega的首席商务官。2018年9月至2020年8月，Sawhney博士在全球投资公司KKR & Co. Inc.任职，担任其美洲医疗保健投资平台的董事，他的工作重点是医疗保健领域的私人和成长型股权投资。2009年7月至2012年8月，Sawhney博士担任诺华公司高级副总裁兼全球企业战略主管，并于2017年2月至2018年2月担任Outcome Health公司战略和业务发展高级副总裁。Sawhney博士还曾于2012年8月至2017年2月担任贝恩公司合伙人，并于1996年至2009年担任波士顿咨询公司合伙人，负责管理生命科学、医疗技术和数字健康领域的众多客户业务。Sawhney博士拥有哈佛医学院的医学博士学位和斯坦福大学的经济学学士学位。
- Roger Sawhney served as Adlai Nortye Ltd.'s director from August 2024 to July 2025 and subsequently re designation from a director to an independent. He has nearly thirty years of financial and strategic expertise across the life sciences industry. Dr. Sawhney currently serves as the Chief Financial Officer of LB Pharmaceuticals, a neuro psych focused Company, based in New York City. From September 2022 to December 2023, Dr. Sawhney served as the Chief Financial Officer of Garuda Therapeutics, Inc. From March 2020 to May 2022, Dr. Sawhney served as the Chief Financial Officer of Omega Therapeutics, Inc., a pioneer in mRNA based therapeutics for precision gene modulation, and he served as the Chief Business Officer of Omega from May 2022 to September 2022. From September 2018 to August 2020, Dr. Sawhney served at KKR & Co. Inc., a global investment firm, as Director of its healthcare investment platform in the Americas where his work focused on investments across private and growth equity in the healthcare sector. From July 2009 to August 2012, Dr. Sawhney served as Senior Vice President and Head of Global Corporate Strategy for Novartis AG, as well as Senior Vice President of Corporate Strategy and Business Development for Outcome Health from February 2017 to February 2018. Dr. Sawhney also served as Partner with Bain & Company from August 2012 to February 2017 and the Boston Consulting Group from 1996 to 2009, where he managed numerous client engagements across the life sciences, med tech and digital health sectors. Dr. Sawhney holds an M.D. from Harvard Medical School and a B.A. in Economics from Stanford University.
- Baozhong Wei
-
鲍忠伟自2025年7月起担任Adlai Nortye Ltd.独立董事。他在公司治理、财务报告、监管合规方面拥有超过19年的经验。自2017年11月起，魏先生担任BR Business Services Pte Ltd的董事，负责监督业务运营并提供战略指导。魏先生在企业融资和咨询服务方面拥有广泛的专业知识。2015年8月至2017年10月，他在BDO Advisory Pte Ltd担任经理助理，专门从事企业融资、估值、财务尽职调查、诉讼支持以及并购活动。在此之前，2014年6月至2015年7月，他在JES International Holdings Limited担任财务经理，负责处理全套公司账户、集团合并、现金流报告，并协助审计程序和税务申报。2012年11月至2014年6月，魏先生在MS Corporate Finance Pte Ltd担任助理经理，专注于公司融资任务，包括公司估值和独立财务顾问服务。魏先生是一名特许会计师（新加坡）和认可税务顾问（公司税和GST）。他也是ACRA注册企业服务提供商和合格的备案代理。魏先生拥有新加坡管理大学金融学硕士学位和牛津布鲁克斯大学会计学学士学位。他在跨境架构、并购和风险管理方面的全面经验，加上他与董事会和审计委员会一起工作的亲身经历，提供了宝贵的财务专业知识和战略洞察力，与公司的公司治理要求非常吻合。
Baozhong Wei has served as Adlai Nortye Ltd.'s independent director since July 2025. He has more than 19 years of experience in corporate governance, financial reporting, and regulatory compliance. Since November 2017, Mr. Wei has served as a director of BR Business Services Pte Ltd, where he oversees business operations and provides strategic guidance. Mr. Wei has extensive expertise in corporate finance and advisory services. From August 2015 to October 2017, he served as an assistant manager at BDO Advisory Pte Ltd, where he specialized in corporate finance, valuation, financial due diligence, litigation support, and merger and acquisition activities. Prior to that, from June 2014 to July 2015, he was a finance manager at JES International Holdings Limited, where he handled full sets of company accounts, group consolidation, cash flow reporting, and assisted with audit procedures and tax filings. From November 2012 to June 2014, Mr. Wei worked as an assistant manager at MS Corporate Finance Pte Ltd, focusing on corporate finance assignments including company valuations and independent financial adviser services. Mr. Wei is a Chartered Accountant (Singapore) and an Accredited Tax Advisor (Corporate Tax and GST). He is also an ACRA registered Corporate Services Provider and qualified Filing Agent. Mr. Wei holds a Master's degree in Finance from Singapore Management University and a Bachelor's degree in Accountancy from Oxford Brookes University. His comprehensive experience in cross border structuring, mergers and acquisitions, and risk management, combined with his hands on experience working alongside boards and audit committees, provides valuable financial expertise and strategic insight that align well with the Company's corporate governance requirements. - 鲍忠伟自2025年7月起担任Adlai Nortye Ltd.独立董事。他在公司治理、财务报告、监管合规方面拥有超过19年的经验。自2017年11月起，魏先生担任BR Business Services Pte Ltd的董事，负责监督业务运营并提供战略指导。魏先生在企业融资和咨询服务方面拥有广泛的专业知识。2015年8月至2017年10月，他在BDO Advisory Pte Ltd担任经理助理，专门从事企业融资、估值、财务尽职调查、诉讼支持以及并购活动。在此之前，2014年6月至2015年7月，他在JES International Holdings Limited担任财务经理，负责处理全套公司账户、集团合并、现金流报告，并协助审计程序和税务申报。2012年11月至2014年6月，魏先生在MS Corporate Finance Pte Ltd担任助理经理，专注于公司融资任务，包括公司估值和独立财务顾问服务。魏先生是一名特许会计师（新加坡）和认可税务顾问（公司税和GST）。他也是ACRA注册企业服务提供商和合格的备案代理。魏先生拥有新加坡管理大学金融学硕士学位和牛津布鲁克斯大学会计学学士学位。他在跨境架构、并购和风险管理方面的全面经验，加上他与董事会和审计委员会一起工作的亲身经历，提供了宝贵的财务专业知识和战略洞察力，与公司的公司治理要求非常吻合。
- Baozhong Wei has served as Adlai Nortye Ltd.'s independent director since July 2025. He has more than 19 years of experience in corporate governance, financial reporting, and regulatory compliance. Since November 2017, Mr. Wei has served as a director of BR Business Services Pte Ltd, where he oversees business operations and provides strategic guidance. Mr. Wei has extensive expertise in corporate finance and advisory services. From August 2015 to October 2017, he served as an assistant manager at BDO Advisory Pte Ltd, where he specialized in corporate finance, valuation, financial due diligence, litigation support, and merger and acquisition activities. Prior to that, from June 2014 to July 2015, he was a finance manager at JES International Holdings Limited, where he handled full sets of company accounts, group consolidation, cash flow reporting, and assisted with audit procedures and tax filings. From November 2012 to June 2014, Mr. Wei worked as an assistant manager at MS Corporate Finance Pte Ltd, focusing on corporate finance assignments including company valuations and independent financial adviser services. Mr. Wei is a Chartered Accountant (Singapore) and an Accredited Tax Advisor (Corporate Tax and GST). He is also an ACRA registered Corporate Services Provider and qualified Filing Agent. Mr. Wei holds a Master's degree in Finance from Singapore Management University and a Bachelor's degree in Accountancy from Oxford Brookes University. His comprehensive experience in cross border structuring, mergers and acquisitions, and risk management, combined with his hands on experience working alongside boards and audit committees, provides valuable financial expertise and strategic insight that align well with the Company's corporate governance requirements.
高管简历
中英对照 | 中文 | 英文- Yang Lu
- 暂无中文简介
Yang Lu serves as Adlai Nortye Ltd.'s chief executive officer and the chairman of Adlai Nortye Ltd.'s board of directors. Mr. Lu has over 20 years of experience in the pharmaceutical industry. Prior to founding Adlai Nortye Ltd.'s company, Mr. Lu worked at Hybio Pharmaceutical Co., Ltd from April 2003 to March 2004. Mr. Lu obtained his bachelor's degree in biotechnology from Xiamen University in July 2002, and his EMBA Executive Master of Business Administration from China Europe International Business School in September 2012. - 暂无中文简介
- Yang Lu serves as Adlai Nortye Ltd.'s chief executive officer and the chairman of Adlai Nortye Ltd.'s board of directors. Mr. Lu has over 20 years of experience in the pharmaceutical industry. Prior to founding Adlai Nortye Ltd.'s company, Mr. Lu worked at Hybio Pharmaceutical Co., Ltd from April 2003 to March 2004. Mr. Lu obtained his bachelor's degree in biotechnology from Xiamen University in July 2002, and his EMBA Executive Master of Business Administration from China Europe International Business School in September 2012.
- Xiaofeng Ye
叶晓峰自2026年4月起担任Adlai Nortye Ltd.首席财务官，2025年1月至2026年4月担任Adlai Nortye Ltd.临时首席财务官，2017年4月至2026年4月担任Adlai Nortye Ltd.业务发展与商业化战略副总裁。在担任之前的职务时，叶博士是全球领先的生物制药解决方案提供商inVentiv Health（现为Syneos Health）的业务发展副总裁。在他任职期间，他在品牌医药产品在美国和欧洲市场的成功商业发布中发挥了关键作用。此外，叶博士通过管理商业业务部门和在中国为跨国制药公司建立医学教育团队，展示了在亚太地区的领导力。在加入inVentiv Health之前，Dr. Ye曾在新泽西州金斯瑞担任区域销售经理，随后在Patheon（现隶属于赛默飞世尔）担任业务发展总监，Patheon是生物制剂CDMO服务的全球领导者。叶博士拥有厦门大学理学学士和理学硕士学位，并在得克萨斯大学MD安德森癌症中心获得博士学位。
Xiaofeng Ye has served as Adlai Nortye Ltd.'s chief financial officer since April 2026, Adlai Nortye Ltd.'s interim chief financial officer from January 2025 to April 2026 and Adlai Nortye Ltd.'s vice president of business development & commercialization strategy from April 2017 to April 2026. In his previous role, Dr. Ye was the Vice President of Business Development at inVentiv Health (now Syneos Health), a leading global biopharma solutions provider. During his tenure, he played a key role in the successful commercial launches of branded pharmaceutical products across the U.S. and European markets. Additionally, Dr. Ye demonstrated leadership in the Asia Pacific region by managing commercial business units and establishing medical education teams for multinational pharmaceutical companies in China. Before his work at inVentiv Health, Dr. Ye served as Regional Sales Manager at GenScript in New Jersey, followed by his role as Business Development Director at Patheon (now part of Thermo Fisher Scientific), a global leader in biologics CDMO services. Dr. Ye holds a Bachelor of Science and a Master of Science from Xiamen University and earned his Ph.D. at the University of Texas MD Anderson Cancer Center.- 叶晓峰自2026年4月起担任Adlai Nortye Ltd.首席财务官，2025年1月至2026年4月担任Adlai Nortye Ltd.临时首席财务官，2017年4月至2026年4月担任Adlai Nortye Ltd.业务发展与商业化战略副总裁。在担任之前的职务时，叶博士是全球领先的生物制药解决方案提供商inVentiv Health（现为Syneos Health）的业务发展副总裁。在他任职期间，他在品牌医药产品在美国和欧洲市场的成功商业发布中发挥了关键作用。此外，叶博士通过管理商业业务部门和在中国为跨国制药公司建立医学教育团队，展示了在亚太地区的领导力。在加入inVentiv Health之前，Dr. Ye曾在新泽西州金斯瑞担任区域销售经理，随后在Patheon（现隶属于赛默飞世尔）担任业务发展总监，Patheon是生物制剂CDMO服务的全球领导者。叶博士拥有厦门大学理学学士和理学硕士学位，并在得克萨斯大学MD安德森癌症中心获得博士学位。
- Xiaofeng Ye has served as Adlai Nortye Ltd.'s chief financial officer since April 2026, Adlai Nortye Ltd.'s interim chief financial officer from January 2025 to April 2026 and Adlai Nortye Ltd.'s vice president of business development & commercialization strategy from April 2017 to April 2026. In his previous role, Dr. Ye was the Vice President of Business Development at inVentiv Health (now Syneos Health), a leading global biopharma solutions provider. During his tenure, he played a key role in the successful commercial launches of branded pharmaceutical products across the U.S. and European markets. Additionally, Dr. Ye demonstrated leadership in the Asia Pacific region by managing commercial business units and establishing medical education teams for multinational pharmaceutical companies in China. Before his work at inVentiv Health, Dr. Ye served as Regional Sales Manager at GenScript in New Jersey, followed by his role as Business Development Director at Patheon (now part of Thermo Fisher Scientific), a global leader in biologics CDMO services. Dr. Ye holds a Bachelor of Science and a Master of Science from Xiamen University and earned his Ph.D. at the University of Texas MD Anderson Cancer Center.
- Archie Tse
Archie Tse自2026年4月起担任Adlai Nortye Ltd.总裁，自2024年3月起担任Adlai Nortye Ltd.研发主管。在加入Adlai Nortye Ltd.之前，Archie Tse博士曾担任基石药业首席科学官、高级副总裁、研究和早期临床开发负责人以及CMC部门负责人。在此之前，谢博士曾在包括MSD和第一三共在内的跨国公司担任领导职务。Tse博士在南加州大学获得医学博士学位和生物化学与分子生物学博士学位。
Archie Tse has served as Adlai Nortye Ltd.'s president since April 2026 and Adlai Nortye Ltd.'s head of research and development since March 2024. Prior to joining Adlai Nortye Ltd., Dr. Archie Tse served as the Chief Scientific Officer, Senior Vice President, Head of Research and Early Clinical Development, and Head of CMC Department of CStone Pharmaceuticals. Before that, Dr. Tse held leadership positions in multinational companies, including MSD and Daiichi Sankyo. Dr. Tse obtained his Doctor of Medicine degree and his Doctor of Biochemistry and Molecular Biology degree from University of Southern California.- Archie Tse自2026年4月起担任Adlai Nortye Ltd.总裁，自2024年3月起担任Adlai Nortye Ltd.研发主管。在加入Adlai Nortye Ltd.之前，Archie Tse博士曾担任基石药业首席科学官、高级副总裁、研究和早期临床开发负责人以及CMC部门负责人。在此之前，谢博士曾在包括MSD和第一三共在内的跨国公司担任领导职务。Tse博士在南加州大学获得医学博士学位和生物化学与分子生物学博士学位。
- Archie Tse has served as Adlai Nortye Ltd.'s president since April 2026 and Adlai Nortye Ltd.'s head of research and development since March 2024. Prior to joining Adlai Nortye Ltd., Dr. Archie Tse served as the Chief Scientific Officer, Senior Vice President, Head of Research and Early Clinical Development, and Head of CMC Department of CStone Pharmaceuticals. Before that, Dr. Tse held leadership positions in multinational companies, including MSD and Daiichi Sankyo. Dr. Tse obtained his Doctor of Medicine degree and his Doctor of Biochemistry and Molecular Biology degree from University of Southern California.